Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2019-07-31 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-07-31 English
FORM F-3
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 registration statement filed with the SEC, which is a type of shelf registration statement used for registering securities for public offering. It includes detailed information about the securities to be offered, the company, risk factors, and other disclosures typical of a registration statement. This is not a financial report, earnings release, or management discussion, but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a brief notice.
2019-07-24 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about the registration of ordinary shares under an award plan, references to the Securities Act of 1933, and contains legal and indemnification information about directors and officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice, but a full registration statement filing.
2019-07-24 English
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It relates to an 'at the market' offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd. The document includes detailed information about the offering, the sales agreement with SVB Leerink LLC, risk factors, use of proceeds, plan of distribution, and other legal and financial disclosures typical of a capital raising filing. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update describing the terms and conditions of a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full prospectus supplement, not just an announcement of a report, supporting a high confidence level.
2019-07-23 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It announces the entry into a Sales Agreement with SVB Leerink LLC for an 'at the market' offering program to sell American Depositary Shares (ADSs) up to $60 million. The document includes details about the sales agreement, commissions, and legal opinions attached as exhibits. There are no financial statements or detailed financial performance data included. The document is primarily an announcement of a capital raising arrangement and related agreements, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is about 4922 characters, sufficient to provide substantive information about the financing arrangement rather than a brief announcement. Hence, the classification is CAP with high confidence.
2019-07-23 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release reporting second quarter 2019 financial results and operational highlights, as well as condensed consolidated interim unaudited financial information for the quarter ended June 30, 2019. Form 6-K filings are typically used to report interim or quarterly financial results and other material information by foreign private issuers. The presence of interim unaudited financial information and the timing (Q2 2019) indicates this is an Interim / Quarterly Report. The document length is 2324 characters, which is consistent with a Form 6-K containing interim financial data rather than a full annual report or just an announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2019-07-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.